Company / Cash & Equivalents
Illumina, Inc. Cash & Equivalents History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$769.0M
FY2017
5-year range
-
FY2016-FY2017
Trend
+4.6%
vs FY2016
Sector context
#36 of 148
Health Care
What the data says
Illumina, Inc.'s cash & equivalents of $769M is higher than 76% of companies in the Health Care sector (FY2017).
Based on SEC 10-K filings.
$769M in FY2017. Top quartile in the Health Care sector.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 148This company $769.0M Sector average $1.2B
▼
-34.7% below sector average
Key checks
Key Insights
- In FY2017, cash & equivalents increased 4.6% year-over-year.
- Ranks #36 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 29.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $769.0M | +4.6% |
| FY2016 | $735.0M | -4.4% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026